KBLB Kraig Biocraft Laboratories Inc.

Kraig Biocraft Laboratories and Kings Group form Spydasilk Enterprises Pte. Ltd., a Singapore based Joint Venture Company, for the marketing and sales of spider silk based products

Kraig Biocraft Laboratories and Kings Group form Spydasilk Enterprises Pte. Ltd., a Singapore based Joint Venture Company, for the marketing and sales of spider silk based products

Kraig’s joint venture with Kings is tied to the previously announced exclusive spider silk purchase and sales agreement valued at up to US$40 million

ANN ARBOR, Mich., April 09, 2021 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company, together with M the Movement, Kings Golden Harvest Pte Ltd (“Kings Group”), has established Spydasilk Enterprises Pte. Ltd. (“Spydasilk Enterprises”) as a Singapore based joint venture.

This partnership represents the Company’s first vertically integrated sales channel.

Spydasilk Enterprises is developing a premium line of luxury streetwear based on Kraig Labs’ spider silk technologies with exclusive sales rights within the Association of Southeast Asian Nations (ASEAN) region. The move positions Kraig Labs and Kings Group to advance their partnership, which began with a previously announced exclusive purchase and sales agreement valued at up to US$40 million.

“Based on our initial efforts, there is a definite demand for spider silk technology and product developers are very excited about working with these super fibers,” said Walter Wee, CIO of Kings Group. “In addition to building up the Spydasilk brand, we must build Spydasilk’s vendor and customer bases. We are already having great success with clients that share our vision and passion for spider silk. We believe that their efforts will further broaden Spydasilk’s market opportunities in multiple industries asides from the fashion industry,” continued Wee.

The new joint venture company will commercialize Kraig Labs’ biodegradable and biocompatible ‘super fibers’, using a scalable and cost-effective spider silk production platform and patented spider silk gene sequences in silkworms.

“This new joint venture is the beginning of the fulfillment of my original vision for Kraig Labs, where we are able to vertically integrate and capture intermediate and end product margins. Thanks to Walter and the Kings Group team, Spydasilk should hit the ground running. We have high expectations for the future of spider silk and Spydasilk Enterprises,” said Kim Thompson, Kraig Labs’ founder and CEO.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to .

About Kings Group and M the Movement

Kings Group is headquartered in Singapore and established regional offices with multiple assets in Indonesia and Vietnam. Kings Group envisions itself to be a forerunner in International Marketing and Trading; bridging domestic businesses and projecting their products internationally.

For further information, please visit .

M the Movement is Kings Group’s premiere eco-friendly luxury streetwear line. Internationally recognized and loved by celebrities globally.

For more information, please visit

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495



EN
09/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kraig Biocraft Laboratories Inc.

 PRESS RELEASE

Kraig Biocraft Laboratories to Launch Operations at New Southeast Asia...

Kraig Biocraft Laboratories to Launch Operations at New Southeast Asia Production Facility This Week New site established in collaboration with a government agency to bolster spider silk output and market readiness ANN ARBOR, Mich., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it will begin operations this week at its newest production facility. This milestone marks the launch of the first full production cycle at the site. This production site was secured earlier ...

 PRESS RELEASE

Kraig Biocraft Laboratories Sets New Production Record and Advances Sp...

Kraig Biocraft Laboratories Sets New Production Record and Advances Spider Silk Reeling with Successful Implementation of Automated Reeling Equipment Improved processing unlocks greater quality and efficiency for recombinant spider silk fiber ANN ARBOR, Mich., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced the recent successful production of reeled raw recombinant spider silk using automated equipment. This batch set a new single run record, processing more than 250...

 PRESS RELEASE

Kraig Biocraft Laboratories Signs Landmark Collaborative Agreement wit...

Kraig Biocraft Laboratories Signs Landmark Collaborative Agreement with Government Agency in Southeast Asia to Advance Spider Silk Production ANN ARBOR, Mich., July 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced the formal signing of a multi-year agreement with a government agency in Southeast Asia to support the scale-up of its recombinant spider silk production. This agreement is the result of many years of groundwork by Kraig Labs and marks a significant step in the Co...

 PRESS RELEASE

Kraig Biocraft Laboratories Successfully Completes Lab-to-Field Transi...

Kraig Biocraft Laboratories Successfully Completes Lab-to-Field Transition for Three New Spider Silk Production Strains Newly Deployed Strains Deliver Strong Performance in Initial Field Rearing Cycles, Paving the Way for Accelerated Deployment of Next-Generation Transgenics ANN ARBOR, Mich., July 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces the successful completion of the first rearing cycles for its three newest recombinant spider silk production strains. These newly deve...

 PRESS RELEASE

Kraig Biocraft Laboratories Nears Strategic Three-Year Government Coll...

Kraig Biocraft Laboratories Nears Strategic Three-Year Government Collaboration to Expand Recombinant Spider Silk Production ANN ARBOR, Mich., July 18, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it is finalizing a significant three-year collaborative agreement with a key government agency in Southeast Asia to expand the scale and security of its recombinant spider silk manufacturing platform. This landmark agreement, expected to be signed before the end of July, marks the ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch